Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells

Xia,Jiyi; Yu,Xiaolan; Song,Xueqin; Li,Gang; Mao,Xiguang; Zhang,Yujiao

doi:10.3892/mmr.2016.6003

Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells

Authors:
- Jiyi Xia
- Xiaolan Yu
- Xueqin Song
- Gang Li
- Xiguang Mao
- Yujiao Zhang
View Affiliations

Affiliations: School of Medical Information and Engineering, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Obstetrics and Gynecology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Obstetrics and Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
Published online on: December 7, 2016 https://doi.org/10.3892/mmr.2016.6003
Pages: 488-494

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is the fourth most common malignancy in women worldwide, and resistance to chemotherapy drugs is the biggest obstacle in the treatment of cervical cancers. In the present study, the molecular mechanisms underlying cisplatin resistance in human cervical cancer cells were investigated. When human cervical cancer cells were treated with 10 µg/ml of cisplatin for 24 and 48 h, high mobility group box 1 (HMGB1) protein expression levels significantly increased in a time‑dependent manner. Comparisons between cisplatin‑sensitive HeLa cells and cisplatin‑resistant HeLa/DDP cells revealed higher levels of HMGB1 in HeLa/DDP cells than in HeLa cells. Additionally, the half maximal inhibitory concentration (IC50) value for cisplatin in HeLa/DDP cells was 5.3‑fold that in HeLa cells. Analysis of the distribution of cellular components revealed that HMGB1 translocation from the nucleus to cytoplasm contributed to cisplatin resistance. This was further confirmed by demonstration that ethyl pyruvate treatment suppressed the cytoplasmic translocation of HMGB1, resulting in inhibition of HeLa cell proliferation. Furthermore, endogenous HMGB1 was inhibited with HMGB1‑specific short hairpin (sh)RNA, and MTT assay results showed that interference with HMGB1 expression reduced cell viability and potentially reversed cisplatin resistance in HeLa cells. Transfection with HMGB1 shRNA was demonstrated to induce cell apoptosis in HeLa cells, as detected by FACS analysis. In addition, administration of recombinant HMGB1 protein in HeLa cells promoted cell autophagy, mediated by the phosphorylation of extracellular signal‑regulated kinase 1/2. Thus, cytoplasmic HMGB1 translocation and HMGB1‑induced cell autophagy are proposed to contribute to cisplatin resistance by inhibiting apoptosis of cervical cancer cells. HMGB1 could, therefore, represent a novel therapeutic target for, and a diagnostic marker of, chemotherapy resistant cervical cancers.

View Figures

View References

1	Boutas I, Sofoudis C, Kalampokas E, Anastasopoulos C, Kalampokas T and Salakos N: Fertility preservation in women with early stage cervical cancer. Review of the literature. Eur J Gynaecol Oncol. 35:373–377. 2014.PubMed/NCBI
2	Arimoto T, Kawana K, Adachi K, Ikeda Y, Nagasaka K, Tsuruga T, Yamashita A, Oda K, Ishikawa M, Kasamatsu T, et al: Minimization of curative surgery for treatment of early cervical cancer: A review. Jpn J Clin Oncol. 45:611–616. 2015. View Article : Google Scholar : PubMed/NCBI
3	Huang QT, Zhong M, Gao YF, Huang LP, Huang Q, Wang W, Wang ZJ and Yu YH: Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth. J Clin Virol. 61:321–328. 2014. View Article : Google Scholar : PubMed/NCBI
4	Mann L, Foley KL, Tanner AE, Sun CJ and Rhodes SD: Increasing cervical cancer screening among us hispanics/latinas: A qualitative systematic review. J Cancer Educ. 30:374–387. 2015. View Article : Google Scholar : PubMed/NCBI
5	Jiang J, Pang H, Liu B, Nasca PC, Zhang B, Wu Y, Han W, Gates M, Lu T, Zou X, et al: Effects of active, passive, and combined smoking on cervical cancer mortality: A nationwide proportional mortality study in Chinese urban women. Cancer Causes Control. 26:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
6	Maguire R, Kotronoulas G, Simpson M and Paterson C: A systematic review of the supportive care needs of women living with and beyond cervical cancer. Gynecol Oncol. 136:478–490. 2015. View Article : Google Scholar : PubMed/NCBI
7	Li H, Wu X and Cheng X: Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
8	Obel J, Souares Y, Hoy D, Baravilala W, Garland SM, Kjaer SK and Roth A: A systematic review of cervical cancer incidence and mortality in the Pacific Region. Asian Pac J Cancer Prev. 15:9433–9437. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gadducci A, Tana R, Cosio S and Cionini L: Treatment options in recurrent cervical cancer (Review). Oncol Lett. 1:3–11. 2010.PubMed/NCBI
10	Smits RM, Zusterzeel PL and Bekkers RL: Pretreatment retroperitoneal para-aortic lymph node staging in advanced cervical cancer: A review. Int J Gynecol Cancer. 24:973–983. 2014. View Article : Google Scholar : PubMed/NCBI
11	Lorusso D, Petrelli F, Coinu A, Raspagliesi F and Barni S: A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 133:117–123. 2014. View Article : Google Scholar : PubMed/NCBI
12	Turan T, Yildirim BA, Tulunay G, Boran N, Yıldız F and Köse MF: Experience in stage IB2 cervical cancer and review of treatment. J Turk Ger Gynecol Assoc. 11:27–37. 2010.PubMed/NCBI
13	Sun R, Jiang B, Qi H, Zhang X, Yang J, Duan J, Li Y and Li G: SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Cell Death Dis. 6:e19902015. View Article : Google Scholar : PubMed/NCBI
14	Andersson U, Erlandsson-Harris H, Yang H and Tracey KJ: HMGB1 as a DNA-binding cytokine. J Leukoc Biol. 72:1084–1091. 2002.PubMed/NCBI
15	Kang R, Zhang Q, Zeh HJ III, Lotze MT and Tang D: HMGB1 in cancer: Good, bad, or both? Clin Cancer Res. 19:4046–4057. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lolmede K, Campana L, Vezzoli M, Bosurgi L, Tonlorenzi R, Clementi E, Bianchi ME, Cossu G, Manfredi AA, Brunelli S and Rovere-Querini P: Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol. 85:779–787. 2009. View Article : Google Scholar : PubMed/NCBI
17	Szénási T, Kénesi E, Nagy A, Molnár A, Bálint BL, Zvara Á, Csabai Z, Deák F, Boros Oláh B, Mátés L, et al: Hmgb1 can facilitate activation of the matrilin-1 gene promoter by Sox9 and L-Sox5/Sox6 in early steps of chondrogenesis. Biochim Biophys Acta. 1829:1075–1091. 2013. View Article : Google Scholar : PubMed/NCBI
18	Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, et al: Autophagy in malignant transformation and cancer progression. EMBO J. 34:856–880. 2015. View Article : Google Scholar : PubMed/NCBI
19	Berardi DE, Campodónico PB, Díaz Bessone MI, Urtreger AJ and Todaro LB: Autophagy: Friend or foe in breast cancer development, progression and treatment. Int J Breast Cancer. 2011:5950922011.PubMed/NCBI
20	Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
21	Xie M, Kang R, Yu Y, Zhu S, He YL, Xu WQ, Tang DL and Cao LZ: Enhancive effect of HMGB1 gene silence on adriamycin-induced apoptosis in K562/A02 drug resistance leukemia cells. Zhonghua Xue Ye Xue Za Zhi. 29:549–552. 2008.(In Chinese). PubMed/NCBI
22	Suren D, Yıldırım M, Demirpençe Ö, Kaya V, Alikanoğlu AS, Bülbüller N, Yıldız M and Sezer C: The role of high mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit. 20:530–537. 2014. View Article : Google Scholar : PubMed/NCBI
23	Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC and Kajdacsy-Balla A: HMGB1: A Promising therapeutic target for prostate cancer. Prostate Cancer. 2013:1571032013.PubMed/NCBI
24	Zhang X, Wang H and Wang J: Expression of HMGB1 and NF-κB p65 and its significance in non-small cell lung cancer. Contemp Oncol (Pozn). 17:350–355. 2013.PubMed/NCBI
25	Ohmori H, Luo Y and Kuniyasu H: Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets. 15:183–193. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lee H, Shin N, Song M, Kang UB, Yeom J, Lee C, Ahn YH, Yoo JS, Paik YK and Kim H: Analysis of nuclear high mobility group box 1 (HMGB1)-binding proteins in colon cancer cells: Clustering with proteins involved in secretion and extranuclear function. J Proteome Res. 9:4661–4670. 2010. View Article : Google Scholar : PubMed/NCBI
27	Bukowska-Durawa A and Luszczynska A: Cervical cancer screening and psychosocial barriers perceived by patients. A systematic review. Contemp Oncol (Pozn). 18:153–159. 2014.PubMed/NCBI
28	Kavallaris A, Zygouris D, Dafopoulos A, Kalogiannidis I and Terzakis E: Nerve sparing radical hysterectomy in early stage cervical cancer. Latest developments and review of the literature. Eur J Gynaecol Oncol. 36:5–9. 2015.PubMed/NCBI
29	Chen S, Li X, Feng J, Chang Y, Wang Z and Wen A: Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells. Med Hypotheses. 77:206–208. 2011. View Article : Google Scholar : PubMed/NCBI
30	Yu L, Gu C, Zhong D, Shi L, Kong Y, Zhou Z and Liu S: Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. Cancer Lett. 355:34–45. 2014. View Article : Google Scholar : PubMed/NCBI